Determine MTD, Evaluate Efficacy and Safety of Genexol®-PM Plus Carboplatin With Advanced Ovarian Cancer

Inclusion Criteria:

* Women ≥ 18 years old.
* Signed informed consent before inclusion.
* Subjects who have histologically or cytologically confirmed advanced epithelial ovarian cancer.(FIGO IIIB-IV)
* Subjects who have measurable disease by RECIST after debulking surgery.
* ECOG performance status of 0, 1, or 2.
* Estimated life expectancy of more than 6 months
* Subjects who have the clinically acceptable function of blood, kidney and liver at screening visit

  * Hb ≥ 10g/dl
  * ANC ≥ 1.5×10\^9/L
  * Platelet Count ≥ 100×10\^9/L
  * Serum total bilirubin ≤ 1.5×ULN
  * Serum AST and ALT ≤ 2.5×ULN
  * Serum ALP ≤ 2.5×ULN
  * Serum creatinine ≤ 1.5×ULN

Exclusion Criteria:

* Subjects who have received chemotherapy for ovarian cancer other than debulking surgery.
* Subjects who have a history of radiotherapy to pelvis or abdominal cavity
* Subjects who receive immunotherapy or hormonal therapy for ovarian cancer
* Subjects who have other malignancies within the past 5 years
* Subjects who have had a major surgery other than debulking surgery within 2 weeks prior to the screening/baseline visit
* Subjects who have a history of metastasis or currently have a metastasis to the central nervous system(CNS)
* Subjects who have a preexisting sensory or motor neuropathy of grade ≥ 1 based on NCI CTCAE V3.0
* Subjects who have serious medical condition

  * Uncontrolled or severe cardiovascular disease(Ischemic heart disease, myocardial infarction within the last 6 months, congestive heart failure)
  * Uncontrollable infection
  * Previous allergic reactions in connection with paclitaxel and carboplatin
* Subjects who participate another clinical trial within the last 4 weeks before inclusion